INTRODUCTION:
In recent years, combining instillation of a topical wound solution with negative pressure wound therapy (NPWT) has facilitated wound cleansing. Furthermore, published studies have positively reported on the use of a NPWT system with automated instillation and a dwell time (NPWTi-d) that provides a method of cyclically instilling and dwelling topical solutions to help improve healing outcomes of acute and chronic wounds. Our purpose was to analyze our outcomes of patients who received adjunctive NPWTi-d with a polyhexanide solution to address surgical site occurrences (SSO) following first stage expander-implant breast reconstruction.
METHODS:
A retrospective record review was conducted. Patient data were extracted from the electronic medical record by means of manual review and stored in a database. Adult patient records were included for analysis if the patient underwent a mastectomy followed by immediate or delayed expander reconstruction, had infection of at least one pocket confirmed via culture, had received oral and systemic antibiotics for at least one week, and subsequently received NPWTid. All procedures were completed between January 1, 2016 and February 1, 2017. Demographics, surgical approach, comorbidities and expander salvage rate were recorded and analyzed.
Six female patients with a median age of 50.8 were included in the analysis. Five of 6 patients had undergone sub-pectoral expander reconstruction and one patient received pre-pectoral expander reconstruction. Antibiotics were also continued based on specific cultures. All surgical site infections were thoroughly debrided and irrigated. Adjunctive NPWTi-d was initiated: instillation of a polyhexanide solution with a 20-minute dwell time, followed by 3.5 hours of -125 mmHg negative pressure. Duration of therapy ranged from 1-3 days. 
INTRODUCTION:
To use a validated patientreported outcomes measure to assess the satisfaction and well-being of adolescent patients before and after surgical treatment for macromastia.
METHODS:
This longitudinal study included adolescent females who were managed in clinic for macromastia and received both pre-and postoperative surveys. All patients who attended shared medical appointments during the study period were administered the preoperative BREAST-Q 1 as a condition-specific measure of satisfaction and wellbeing. Patients who received surgical treatment were also administered the postoperative BREAST-Q at least 3 months after surgery. BREAST-Q scores range from 0-100 for each tested domain, with 100 corresponding to highest well-being or satisfaction. In addition, we recorded grams of breast tissue removed during surgery and postoperative complications.
EXPERIENCE:
During the study period, 22 patients who attended shared medical appointments were scheduled for reduction mammoplasty. Six surgeries were cancelled due to inability to obtain insurance coverage. The remaining 16 patients received surgery, eight of whom have taken follow-up surveys and were thus included in this analysis.
RESULTS:
For BREAST-Q domains that were measured pre-and postoperatively, the average scores significantly increased after surgery as follows: satisfaction with breasts increased from 21.8 to 76.0 (p=0.01), psychosocial well-being increased from 40.1 to 85.3 (p=0.04), and physical wellbeing increased from 24.6 to 83.6 (p=0.01). There was not a significant increase for sexual well-being, though average score increased from 35.8 to 72.8 (p=0.68). Postoperatively, patients also reported an average score of 92.6 for satisfaction with outcome, 81.3 for satisfaction with information, 82.4 for satisfaction with nipples, 100 for satisfaction with surgeon, 100 for satisfaction with medical staff, and 100 for satisfaction with office staff. The average weight of breast tissue removed was 802.0 grams per side.
CONCLUSION: This is the first report of adolescent satisfaction and well-being before and after breast reduction surgery using the BREAST-Q. Given that we saw a significant increase in patient well-being and satisfaction after surgical treatment, the BREAST-Q should continue to be validated in the adolescent population so plastic surgeons can further demonstrate the functional and psychosocial benefits of adolescent reduction mammoplasties to third-party payors.
